TY - JOUR
T1 - Mapping of epitopes on the BP180 ectodomain targeted by IgA and IgG autoantibodies in patients with the lamina lucida-type of linear IgA disease
AU - Georgi, Matthias
AU - Scheckenbach, Christian
AU - Kromminga, Arno
AU - Partscht, Karin
AU - Messer, Gerald
AU - Bröcker, E. B.
AU - Zillikens, D.
N1 - Funding Information:
Acknowledgements This work was supported by grant 98.073.1 from the Wilhelm Sander-Stiftung, Munich, Germany (Dr. Zil-likens). The authors are grateful to Drs. Takashi Hashimoto and Zhuxiang Nie (Department of Dermatology, Kurume University, Fukuoka, Japan) for providing the recombinant GST fusion proteins used in this study. We also thank Christine Hagel (Hamburg), and Silvana Noll and Stanislaus Reimer (Würzburg) for technical assistance. Drs. Kiehl (Hannover), Meurer (Dresden), Ogilvie (Er-langen), Sticherling (Kiel), and Stolz (Regensburg) kindly provided some of the patients’ serum samples.
PY - 2001
Y1 - 2001
N2 - Linear IgA disease (LAD) is an autoimmune subepidermal blistering skin disease characterized by the linear deposition of IgA at the dermoepidermal junction. Serum from patients with LAD most commonly contains autoantibodies that are directed against the hemidesmosomal transmembrane glycoprotein BP180 (type XVII collagen). Various antigenic sites on the extracellular domain of this anchoring filament protein have been shown to be targeted by autoantibodies in different autoimmune bullous skin diseases, including bullous pemphigoid and cicatricial pemphigoid (CP). However, little is known about epitopes on BP180 recognized by autoantibodies in LAD. In this study, we used three recombinant GST fusion proteins, together roughly covering the entire BP180 ectodomain, to characterize the autoimmune response in serum from patients with LAD. Interestingly, we found both IgA and IgG reactivity to all three portions of the BP180 ectodomain. The strongest reactivity was observed with the C-terminal portion of BP180. This is also the major region recognized by autoantibodies in patients with CP. This finding correlates with the observation that there may be significant overlap of the clinical and immunopathological findings in LAD and CP.
AB - Linear IgA disease (LAD) is an autoimmune subepidermal blistering skin disease characterized by the linear deposition of IgA at the dermoepidermal junction. Serum from patients with LAD most commonly contains autoantibodies that are directed against the hemidesmosomal transmembrane glycoprotein BP180 (type XVII collagen). Various antigenic sites on the extracellular domain of this anchoring filament protein have been shown to be targeted by autoantibodies in different autoimmune bullous skin diseases, including bullous pemphigoid and cicatricial pemphigoid (CP). However, little is known about epitopes on BP180 recognized by autoantibodies in LAD. In this study, we used three recombinant GST fusion proteins, together roughly covering the entire BP180 ectodomain, to characterize the autoimmune response in serum from patients with LAD. Interestingly, we found both IgA and IgG reactivity to all three portions of the BP180 ectodomain. The strongest reactivity was observed with the C-terminal portion of BP180. This is also the major region recognized by autoantibodies in patients with CP. This finding correlates with the observation that there may be significant overlap of the clinical and immunopathological findings in LAD and CP.
UR - http://www.scopus.com/inward/record.url?scp=0035088443&partnerID=8YFLogxK
U2 - 10.1007/s004030000205
DO - 10.1007/s004030000205
M3 - Journal articles
C2 - 11357223
AN - SCOPUS:0035088443
SN - 0340-3696
VL - 293
SP - 109
EP - 114
JO - Archives of Dermatological Research
JF - Archives of Dermatological Research
IS - 3
ER -